Indirubin Derivative E804 is a cell-permeable indirubin derivative (IDR) that inhibits the Src-Stat3 signaling pathway and displays anti-tumor properties. A potent, ATP-competitive inhibitor of the kinase activities of Src. Indirubin Derivative E804 decreases tyrosine phosphorylation levels of Src, JAK1, and Stat3 in MDA-MB-468 cells in a time- and dose-dependent manner. Selectively induces apoptosis in cells expressing high levels of active Stat3. Indirubin Derivative E804 is an inhibitor of Cdc2, Cdk2 and SRC.
1. Nam, S. et al. 2005. Proc. Natl. Acad. Sci. U.S.A. 102(17): 5998-6003. PMID: 15837920
Soluble in DMSO (200 mg/ml).
Store at -20° C
262.70° C (Predicted)
719.8° C at 760 mmHg (Predicted)
1.4 g/cm3 (Predicted)
n20D 1.70 (Predicted)
Kinase activities of Src: IC50 = 430 nM; Cdk1/cyclin E : IC50 = 210 nM; Cdk2/cyclin A: IC50 = 540 nM; Cdk1/cyclin B : IC50 = 1.65 µM; Interferon-induced, double-stranded RNA-activated protein kinase: IC50 = <100 nM (human)
pKa: 10.55 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
bvseo_sdk, java_sdk, bvseo-3.2.0
CLOUD, getContent, 72ms
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
A decrease in MclA decrease in Mcl-1 expression was observed in MDA-MB-468 cells by WB when comparing untreated cells with those that have been treated with Indirubin Derivative E804, a cell permeable inhibitor of Src-Stat3. -SCBT QC
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.Hide
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.